Pooled Safety and Long-Term Results

ACR=American College of Rheumatology; AE=adverse event; BID=twice daily; CI=confidence interval; csDMARD=conventional synthetic disease-modifying antirheumatic drug; GI=gastrointestinal; ILD=interstitial lung disease; JAK=Janus kinase; JAKi=Janus kinase inhibitor; LTE=long-term extension; MACE=major adverse cardiovascular event; MOA=mechanism of action; NMSC=nonmelanoma skin cancer; pt-yr=patient-year; RA=rheumatoid arthritis; TADD=total average daily dose.
References: 1. XELJANZ/XELJANZ XR [prescribing information]. New York, NY: Pfizer Inc.; December 2019. 2. Data on file. Pfizer Inc., New York, NY. 3. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253-1262. 4. Wollenhaupt J, Silverfield J, Lee EB, et. al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837-852.